Literature DB >> 12419488

The effects of nicotinamide on energy metabolism following transient focal cerebral ischemia in Wistar rats.

Jun Yang1, Lori K Klaidman, Artak Nalbandian, Jasmine Oliver, Mei L Chang, Pak H Chan, James D Adams.   

Abstract

This study examined the effects of nicotinamide on adenosine triphosphate (ATP) and nicotinamide adenine (NAD) levels and poly(adenosine diphosphate-ribose) (poly(ADP-ribose)) polymerase activity following ischemia and reperfusion in ketamine pretreated rats. Nicotinamide was administered at the end of the ischemic period. Nicotinamide protected against the depletion of ATP and NAD at 6 and 24 h of reperfusion. Nicotinamide is known to inhibit poly(ADP-ribose) polymerase at early time points, but was found to increase poly(ADP-ribose) polymerase activity at 24 h of reperfusion. It appears that nicotinamide can help maintain cellular energetics during reperfusion, thereby protecting cells from necrotic and apoptotic mechanisms.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12419488     DOI： 10.1016/s0304-3940(02)01005-4

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN： 0304-3940            Impact factor:   3.046


  26 in total

1.  Protective function of nicotinamide against ketamine-induced apoptotic neurodegeneration in the infant rat brain.

Authors:  Najeeb Ullah; Ikram Ullah; Hae Young Lee; Muhammad Imran Naseer; Park Moon Seok; Jawad Ahmed; Myeong Ok Kim
Journal:  J Mol Neurosci       Date:  2011-12-08       Impact factor: 3.444

2.  Preclinical efficacy testing in middle-aged rats: nicotinamide, a novel neuroprotectant, demonstrates diminished preclinical efficacy after controlled cortical impact.

Authors:  Alicia A Swan; Rupa Chandrashekar; Jason Beare; Michael R Hoane
Journal:  J Neurotrauma       Date:  2011-01-09       Impact factor: 5.269

3.  Vulnerability to a Metabolic Challenge Following Perinatal Asphyxia Evaluated by Organotypic Cultures: Neonatal Nicotinamide Treatment.

Authors:  R Perez-Lobos; C Lespay-Rebolledo; A Tapia-Bustos; E Palacios; V Vío; D Bustamante; P Morales; M Herrera-Marschitz
Journal:  Neurotox Res       Date:  2017-06-19       Impact factor: 3.911

4.  NAD+ depletion is necessary and sufficient for poly(ADP-ribose) polymerase-1-mediated neuronal death.

Authors:  Conrad C Alano; Philippe Garnier; Weihai Ying; Youichirou Higashi; Tiina M Kauppinen; Raymond A Swanson
Journal:  J Neurosci       Date:  2010-02-24       Impact factor: 6.167

Review 5.  Modeling chick to assess diabetes pathogenesis and treatment.

Authors:  Savita P Datar; Ramesh R Bhonde
Journal:  Rev Diabet Stud       Date:  2011-08-10

6.  NAD replenishment with nicotinamide mononucleotide protects blood-brain barrier integrity and attenuates delayed tissue plasminogen activator-induced haemorrhagic transformation after cerebral ischaemia.

Authors:  Chun-Chun Wei; Yuan-Yuan Kong; Xia Hua; Guo-Qiang Li; Si-Li Zheng; Ming-He Cheng; Pei Wang; Chao-Yu Miao
Journal:  Br J Pharmacol       Date:  2017-09-06       Impact factor: 8.739

7.  A comparison of the effects of nicotinamide and progesterone on functional recovery of cognitive behavior following cortical contusion injury in the rat.

Authors:  Todd C Peterson; Gail D Anderson; Eric D Kantor; Michael R Hoane
Journal:  J Neurotrauma       Date:  2012-11-27       Impact factor: 5.269

Review 8.  Mitochondrial dysfunction and NAD(+) metabolism alterations in the pathophysiology of acute brain injury.

Authors:  Katrina Owens; Ji H Park; Rosemary Schuh; Tibor Kristian
Journal:  Transl Stroke Res       Date:  2013-08-10       Impact factor: 6.829

9.  Nicotinamide reduces hypoxic ischemic brain injury in the newborn rat.

Authors:  Yangzheng Feng; Ian A Paul; Michael H LeBlanc
Journal:  Brain Res Bull       Date:  2005-12-15       Impact factor: 4.077

10.  Variation in chronic nicotinamide treatment after traumatic brain injury can alter components of functional recovery independent of histological damage.

Authors:  Michael R Hoane; Jeremy L Pierce; Nicholas A Kaufman; Jason E Beare
Journal:  Oxid Med Cell Longev       Date:  2008 Oct-Dec       Impact factor: 6.543
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.